Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.7% – Here’s Why

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) fell 6.7% during mid-day trading on Wednesday . The company traded as low as $21.72 and last traded at $21.9420. 1,059,456 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 1,364,818 shares. The stock had previously closed at $23.52.

Analyst Upgrades and Downgrades

CAPR has been the subject of several recent research reports. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. HC Wainwright upped their target price on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Finally, Roth Mkm boosted their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.82.

Capricor Therapeutics Stock Down 3.2%

The business’s fifty day moving average is $23.30 and its 200-day moving average is $12.50. The stock has a market capitalization of $1.00 billion, a PE ratio of -12.16 and a beta of 0.22.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). As a group, sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GoalVest Advisory LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at approximately $59,000. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares in the last quarter. Legal & General Group Plc boosted its position in Capricor Therapeutics by 8.4% during the 2nd quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 3,205 shares during the period. Rhumbline Advisers increased its holdings in Capricor Therapeutics by 7.3% in the 2nd quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 3,636 shares in the last quarter. Finally, Farther Finance Advisors LLC purchased a new position in Capricor Therapeutics in the third quarter valued at about $28,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.